DEI Trailblazers to Be Honoured at Bermuda Risk Summit
Two Diversity, Equity and Inclusion (DEI) Trailblazers will be honoured at the second annual Bermuda Risk Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR), EY and Gallagher Re.
Chlora Lindley-Myers, National Association of Insurance Commissioners (NAIC) President and Director of the Missouri Department of Commerce and Insurance, and Cheryl Ann Lister, Acting Financial Secretary, Government of Bermuda will be presented DEI Trailblazer Awards by Bermuda’s Premier, the Hon. E. David Burt, JP, MP.
John Huff, CEO, ABIR who will host the awards ceremony on March 6, said, “As ABIR celebrates its 30th Anniversary in 2023, we wanted to recognise Chlora Lindley-Myers as the first woman of colour in 152 years to be elected NAIC President. Of course, we could not let this moment pass without also recognising local hero, Cheryl Ann Lister who was appointed Chair and CEO of Bermuda’s integrated financial services regulator, the Bermuda Monetary Authority (BMA) back in 2002. The day after the DEI Trailblazer Awards, March 7, current BMA CEO, Craig Swan will moderate a discussion about international markets and regulatory cooperation with Tom Sullivan, Former Senior Associate Director, US Federal Reserve, and Alaska Insurance Director, Lori K. Wing-Heier representing the NAIC, just some of the regulators, along with the Bank of England’s Prudential Regulatory Authority, travelling here to participate in the Bermuda Risk Summit.”
David Hart, CEO, BDA said, “We are so pleased to have such senior-level standard setters and risk industry giants coming to Bermuda for our second annual Bermuda Risk Summit from March 6-8, 2023. We are sure to have something of interest for everyone in our dynamic agenda of world-class speakers. In addition to cutting-edge content, there will also be C-suite networking opportunities at our signature and ancillary events.”
Registered attendees of the Bermuda Risk Summit may also enjoy participating in Aon’s Networking Reception, which will be held on Sunday, 5 March 2023, from 5 p.m. at the Flagpole Terrace, followed by the Bermuda Risk Summit’s official Opening Reception, sponsored by SS&C Technology, on Monday, 6 March from 5 p.m. at 1609 Bar & Restaurant. On Tuesday 7 March from 2.30 p.m., AM Best will hold an Insurance Briefing and Networking Reception at the Hamilton Princess, and the Bermuda Risk Summit will be brought to a fantastic close via our Bermuda Lunch Cruise leaving the dock at Hamilton Princess promptly at 1 p.m. on Wednesday, 8 March.
The BDA once again thanks its headline sponsors, ABIR, EY and Gallagher Re; diamond sponsor, Hyperexponential; Gold sponsor, SS&C; silver sponsors AM Best and Kirkland & Ellis; and supporting sponsors, Aon, Bermuda Brokers, Demotech, Docosoft, Florida Insurance Council, KPMG, Meenan P.A., MS Reinsurance, and Rein4ce. Our official media partner is The Insurer and Goslings is our spirits partner.
The BDA is pleased that representatives from the Bermuda’s Women in Reinsurance (WiRe) group, LINK Bermuda, and Association for Corporate Racial Equity (ACRE) will be in attendance, as well as several BDA and ABIR sponsored students from Bermuda College.
The level of registrations received to date has been excellent, but some spaces are still available. Click here to register – the full agenda is available here.
NOTE TO EDITORS: Founded in 1871, the NAIC is a US-based standard-setting organization governed by the chief insurance regulators from the 50 US states, the District of Columbia, and five US territories, to coordinate the regulation of multistate insurers.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223006018/en/
Contact information
Stuart Roberts, Director of Communications & PR
stuart@bda.bm | +1 441 292 7774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release
TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom